The future of clinical development is digital. From wearable sensors to AI-powered analysis, sponsors who embrace digital strategies will gain faster decisions, better data, and stronger regulatory confidence. Get a ste...
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
-
Overcoming data flow challenges in cell therapy trials
How data flows in cell therapy studies differ from other studies and strategies to manage the high volume of data in CGT trials is highlighted in this Q&A with ICON expert Olivier Saulin.
-
Lessons from the first generation of cell and gene oncology trials
ICON’s Tamie Joeckel and Brandon Fletcher take us through best practice approaches to CGT studies and discuss what the future could hold for this exciting area.
-
Best practices in managing CGT from protocol design to data management
Though the fields of immunotherapy and cell and gene therapies have seen significant growth since April 2012, CGT clinical research remains a challenge. ICON's Tamie Joeckel offers expert commentary on managing and executing CGT clinical trials.
-
The quest for increased efficiency in personalised medicine clinical trials
A thought leadership piece by Lawrence Johnson and Cynthia Spittle discussing personalised medicine and how digital devices can improve treatment across a wide spectrum of conditions (pages 16-17).
-
Navigating cell therapy manufacturing amid pandemic woes
An article featuring expert commentary from ICON's Tamie Joeckel on supply-chain strategies to help mitigate vulnerabilities in both autologous and allogeneic cell therapy manufacturing.
-
Navigating complexity in oncology cell and gene therapy clinical trials
This article featured in ClinicalOmics 'Insider's guide to precision medicine 2020' (pages 48 & 49) considers how cell and gene therapies are playing an increasingly important role in treating oncology patients.
-
Transforming cell and gene therapy trial design and execution
With over 400 dedicated Cell and Gene Therapy professionals globally, ICON has developed tools and best practices to transform CGT trial design and execution.
-
-
Adoptive Cell Transfer (ACT) Clinical Trials: The Long Road
ICON’s Martin Lachs and Brandon Fletcher provide expert commentary on Adoptive Cell Transfer (ACT) clinical trials in this July 2019 DDN News article.
